Hepatitis C Virus (HCV)

CAS No.	Product Name	Inquiry
	Artemisinin-d4 Artemisinin-d4 (Qinghaosu-d4) is the deuterium labeled Artemisinin. Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial drug isolated from the aerial parts of Artemisia annua L. plants. It inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects.
	Coblopasvir Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection
	Daclatasvir-d16 Daclatasvir-d16 is a labelled Daclatasvir which inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).
	FNC-TP-trisodium FNC-TP trisodium is the intracellular active form of FNC. FNC is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV.
	HCV-IN-38 HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC50=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile.
1000787-75-6	Tegobuvir Tegobuvir is a non-nucleoside nonstructural protein (NS)5B polymerase inhibitor.
1001426-49-8	IMB-26 IMB-26 is a HCV inhibitor with an EC50 of 2.1 μM. IMB-26 shows potent an anti-HCV activity.
1007882-23-6	HCV-IN-30 HCV-IN-30 is an inhibitor of HCV NS5A replication complex with IC50s of 901 and 102 nM against genotypes 1a and 1b replicons, respectively.
1009119-64-5	Daclatasvir Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).
1009119-83-8	HCV-IN-29 HCV-IN-29 is an inhibitor of hepatitis C virus (HCV). (Exacted from patent US8329159B2, compound 1e)
1015073-42-3	Sofosbuvir Impurity 31 PSI-7409, the active 5'-triphosphate metabolite of PSI-7851, is a potent inhibitor of the HCV NS5B RNA dependent RNA polymerase.
1026785-55-6	Lomibuvir Lomibuvir is an nonnucleoside NS5B polymerase inhibitor. It inhibits the 1b/Con1 HCV subgenomic replicon. It binds to the HCV polymerase with dissociation constants of 17 nM. It demonstrated effective antiviral efficacy and may be used for the treatment of HCV. It was developed by ViroChem Pharma, which was acquired by Vertex Pharmaceuticals in 2009. It is in clinical phase 2 with no progress.
1026785-59-0	VX-222 (VCH-222, Lomibuvir) VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.
102841-43-0	b-D-Xylopyranoside,3-(6,7-dihydro-6-hydroxy-7,7-dimethyl-5H-furo[3,2-g][1]benzopyran-2-yl)-5-hydroxyphenyl Antioxidant activity.
1036915-08-8	IDX184 IDX184 is a potent and orally bioavailable HCV replication inhibitor that potently inhibits HCV polymerase with an IC50 of 0.31 μM and a Ki of 52.3 nM.
104987-36-2	Oenothein B Oenothein B is a dimeric macrocyclic ellagitannin with a wide range of pharmacological activities, including antioxidant, anti-inflammatory, anti-fungal, anti-HCV and anti-tumor properties. It is an effective and specific inhibitor of poly(ADP-ribose) glycohydrolase.
107622-80-0	4-Phenoxybenzylamine 4-Phenoxybenzylamine inhibits the function of HCV NS3 protein by stabilizing the inactive conformation with an IC50 of about 500 μM against FL NS3/4a.
1132936-00-5	ABT-072 ABT-072 is a potent and orally active non-nucleoside HCV NS5B polymerase inhibitor with EC50s of 1 nM and 0.3 nM for HCV GT1a and HCV GT1b, respectively.
1132940-11-4	Dasabuvir-sodium Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b(strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively.
1132940-31-8	ABT-072 potassium trihydrate ABT-072 potassium trihydrate is a potent and orally active non-nucleoside HCV NS5B polymerase inhibitor with EC50s of 1 nM and 0.3 nM for HCV GT1a and HCV GT1b, respectively.

※ Please kindly note that our services are for research use only.